

IFW

Attorney Docket No. 9233-108

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Kenneth D. James et al.

Confirmation No.: 9468

Application No.: 10/723,933

Filed: November 26, 2003

For: NATRIURETIC COMPOUNDS, CONJUGATES, AND USES THEREOF

June 17, 2004

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)**

Sir:

Attached is a list of documents on Form PTO-1449, together with a copy of any listed foreign patent document and/or non-patent literature. A copy of any listed U.S. patent and/or U.S. patent application publication is not provided herewith in accordance with the waiver by the U.S. Patent and Trademark Office of requirements under 37 C.F.R. § 1.98(a)(2)(i) for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC § 371 after June 30, 2003. It is requested that these documents be considered by the Examiner and officially made of record in accordance with the provisions of 37 C.F.R. § 1.56 and Section 609 of the MPEP.

No fee is believed due. However, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220.

Respectfully submitted,

  
Shawna Cannon Lemon  
Registration No. 53,888


Myers Bigel Sibley & Sajovec, P.A.  
P. O. Box 37428  
Raleigh, North Carolina 27627  
Telephone: (919) 854-1400  
Facsimile: (919) 854-1401  
Customer No. 20792

**CERTIFICATE OF MAILING UNDER 37 CFR § 1.10**

"Express Mail" mailing label number EV 381445270 US

Date of Deposit: June 17, 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop Amendment, Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

  
Susan E. Freedman  
Date of Signature: June 17, 2004

**FORM PTO-1449** U.S. Department of Commerce  
Patent and Trademark Office

Attorney Docket Number  
9233-108

Serial No.  
10/723,933

**LIST OF DOCUMENTS CITED BY APPLICANT**

(Use several sheets if necessary)

Applicants:

James et al.

Filing Date

November 26, 2003

Group

**U. S. PATENT DOCUMENTS**

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	A1.	4,569,794	02/11/86	Smith et al.			
	A2.	4,904,763	02/27/90	Matsuo et al.			
	A3.	5,702,910	12/30/97	Numata et al.			
	A4.	5,827,674	10/27/98	Numata et al.			
	A5.	5,859,203	01/12/99	Numata et al.			
	A6.	5,948,761	09/07/99	Seilhamer et al.			
	A7.	6,037,143	03/14/00	Wagner et al.			
	A8.	2002/0025559	02/28/02	Tsuji et al.			
	A9.	2002/0086843	07/04/02	Sudoh et al.			
	A10.	2003/0022235	01/30/03	Dahlen et al.			
	A11.	2003/0055461	03/20/03	Girouard et al.			
	A12.	2003/0069186	04/10/03	Burnett, JR. et al.			
	A13.	2003/0087808	05/08/03	Soltero et al.			
	A14.	2003/0109430	06/12/03	Seilhamer et al.			
	A15.	2004/0002458	01/01/04	Seilhamer et al.			
	A16.	2004/0005669	01/08/04	Stahl et al.			

**FOREIGN PATENT DOCUMENTS**

		Document Number	Date	Country	Class	Subclass	Translation Yes   No
	A17.	WO89/12069 A1	12/14/89	PCT	C07K	13/00	Yes
	A18.	0 542 255 A1	05/19/93	EP	C12P	21/08	Yes
	A19.	0 350 218 B1	04/06/94	EP	C12N	5/12	Yes
	A20.	0 542 255 B1	02/17/99	EP	C12P	21/08	Yes
	A21.	WO 99/07735 A2	02/18/99	PCT	C07K	14/00	Yes
	A22.	WO 00/14351 A1	03/16/00	PCT	E04B	1/68	Yes

**DATE CONSIDERED**

EXAMINER  
\*EXAMINER

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449 U.S. Department of Commerce  
Patent and Trademark Office

Attorney Docket Number  
9233-108

Serial No.  
10/723,933

LIST OF DOCUMENTS CITED BY APPLICANT

(Use several sheets if necessary)

Applicants:

James et al.

Filing Date

November 26, 2003

Group

A23.	I 030 177 A1	08/23/00	EP	G01N	33/48	Yes
A24.	WO 00/71576 A2	11/30/00	PCT	A61K	48/00	Yes
A25.	WO 00/71576 A3	11/30/00	PCT	A61K	48/00	Yes
A26.	0 528 686 B1	11/05/03	EP	C12N	15/62	Yes

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

A27.	Beltowski, J., "N-terminal atrial natriuretic peptides", <i>Postepy Hig Med Dosw</i> , <b>54</b> (6):895-914 (2000)
A28.	Brookes, L. "REDHOT: Rapid Emergency Department Heart Failure Outpatient Trial" Presented at the 7 <sup>th</sup> Annual Scientific Meeting of the Heart Failure Society of America; Las Vegas, NV (September 2003)
A29.	Carvajal et al. "Natriuretic Peptide-Induced Relaxation of Myometrium from the Pregnant Guinea Pig Is Not Mediated By Guanylate Cyclase Activation" <i>The Journal of Pharmacology and Experimental Therapeutics</i> <b>297</b> (1): 181-188 (2001)
A30.	Cermak et al. "Natriuretic Peptides Increase a K <sup>+</sup> Conductance in Rat Mesangial Cells" <i>Pflugers Arch: European Journal of Physiology</i> <b>431</b> (4): 571-5777 (February 1996) Abstract
A31.	Chatterjee, K. "Primary Diastolic Heart Failure" <i>Am J Geriatr Cardiol</i> <b>11</b> (3): 178-189 (2002)
A32.	Chen et al. "Maximizing the Natriuretic Peptide System in Experimental Heart Failure" <i>Circulation</i> <b>999</b> -1003 (2001)
A33.	Chen et al. "Subcutaneous Administration of Brain Natriuretic Peptide in Experimental Heart Failure" <i>Journal of the American College of Cardiology</i> <b>36</b> (5): 1706-1712 (2000)
A34.	Fukuzawa et al. "B-type Natriuretic Peptide Isolated from Frog Cardiac Ventricles" <i>Biochem Biophys Res Commun</i> <b>222</b> (2): 323-329 (May 1996) Abstract
A35.	Gäken et al. "Fusogene Vectors: A Novel Strategy for the Expression of Multiple Genes from a Single Cistron" <i>Gene Therapy</i> <b>7</b> : 1979-1985 (2000)
A36.	Garlichs et al. "Priming of Superoxide Anion in Polymorphonuclear Neutrophils by Brain Natriuretic Peptide" <i>Life Sciences</i> <b>65</b> (10): 1027-33 (1999)
A37.	Gattis, W.A. "Metoprolol CR/XL in the Treatment of Chronic Heart Failure" <i>Pharmacotherapy</i> <b>21</b> (5): 604-613 (2001)
A38.	Heijbel, A. "Purification of a Protein Tagged with (His) <sub>6</sub> at its N-Terminus, C-Terminus, and Both N- and C-Termini Using Different Ions" <i>Life Science News</i> <b>15</b> (2003)
A39.	Hunt et al., "The amino-terminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma", <i>Biochem Biophys Res Commun</i> , <b>214</b> (3):1175-83 (1995)
A40.	Kambayashi et al. "Biological Characterization of Human Brain Natriuretic Peptide (BNP) and Rat BNP: Species-Specific Actions of BNP" <i>Biochemical and Biophysical Research Communications</i> <b>173</b> (2): 599-605 (1990)
A41.	Koller et al. "Molecular Biology of the Natriuretic Peptides and Their Receptors" <i>Circulation</i> <b>86</b> (4) 1081-1088 (October 1992)
A42.	Krum et al. "Diagnostic and therapeutic potential of the endothelin system in patients with chronic heart failure" <i>Heart Fail Rev</i> <b>6</b> (4): 341-52 (December 2001)

EXAMINER  
\*EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce  
Patent and Trademark Office

Attorney Docket Number  
9233-108

Serial No.  
10/723,933

LIST OF DOCUMENTS CITED BY APPLICANT

(Use several sheets if necessary)

Applicants:

James et al.

Filing Date

November 26, 2003


Group

- |      |  |
|------|--|
| A43. | Lindsay et al. "Acetoacetylation of Insulin" <i>Biochem. J.</i> <b>115</b> : 587-595 (1969)  |
| A44. | Lindsay et al. "The Acetylation of Insulin" <i>Biochem. J.</i> <b>121</b> : 737-745 (1971)   |
| A45. | Lisy et al. "Therapeutic Actions of a New Synthetic Vasoactive and Natriuretic Peptide, Dendroaspis Natriuretic Peptide, in Experimental Severe Congestive Heart Failure" <i>Hypertension--Abstracts</i> <b>37</b> (4):1089 (2001) |
| A46. | Luchner et al. "Differential Atrial and Ventricular Expression of Myocardial BNP During Evolution of Heart Failure" <i>Am J Physiol</i> <b>274</b> (Heart Circ. Physiol. 43): H1684-1689 (1998)                                    |
| A47. | Magga et al., "B-type natriuretic peptide: a myocyte-specific marker for characterizing load-induced alterations in cardiac gene expression", <i>Ann Med.</i> <b>30</b> (1):39-45 (1998)   |
| A48. | Mills, G.L. "Observations on the Composition and Activity of Partially Arylated Insulin" <i>Courtauld Institute of Biochemistry, Middlesex Hospital Medical School, London</i> <b>53</b> : 37-40 (1953)                            |
| A49. | Mimeault et al. "Evaluation of Conformational and Binding Characteristics of Various Natriuretic Peptides and Related Analogs" <i>Biochemistry</i> <b>34</b> (3): 955-964 (1995)   |
| A50. | Minamino et al. "Isolation and Identification of a High Molecular Weight Brain Natriuretic Peptide in Porcine Cardiac Atrium" <i>Biochemical and Biophysical Research Communications</i> <b>157</b> (1): 402-409 (1988)            |
| A51. | Muders et al., "Evaluation of plasma natriuretic peptides as markers for left ventricular dysfunction", <i>Am Heart J.</i> <b>134</b> (3):442-9 (1997)   |
| A52. | Nagaya et al. "Plasma Brain Natriuretic Peptide as a Prognostic Indicator in Patients with Primary Hypertension" <i>Circulation</i> <b>102</b> (8): 865-870 (August 2000) Abstract   |
| A53. | Ohba et al. "Effects of Prolonged Strenuous Exercise on Plasma Levels of Atrial Natriuretic Peptide and Brain Natriuretic Peptide in Healthy Men" <i>Am Heart J</i> <b>141</b> (5):751-758 (May 2001) Abstract                     |
| A54. | Oliver et al. "Natriuretic Peptide Receptor 1 Expression Influences Blood Pressures of mice in Dose-Dependent Manner" <i>Proc. Natl. Acad. Sci. USA</i> <b>95</b> : 2547-2551 (March 1998)   |
| A55. | Pemberton et al. "Amino-Terminal proBNP in Ovine Plasma: Evidence for Enhanced Secretion in Response to Cardiac Overload" <i>Am. J. Physiol.</i> <b>275</b> (Heart Circ. Physiol. 44): H1200-1208 (1998)                           |
| A56. | Potter et al. "Identification and Characterization of the Major Phosphorylation Sites of the B-type Natriuretic Peptide Receptor" <i>The Journal of Biological Chemistry</i> <b>273</b> (25): 15533-15539 (June 1998)              |
| A57. | Ravnan et al. "Diuretic Resistance and Strategies to Overcome Resistance in Patients with Congestive Heart Failure" <i>CHF</i> <b>8</b> (2):80-85 (2002)   |
| A58. | Schoenfeld et al. "Agonist Selectivity for Three Species of Natriuretic Peptide Receptor-A" <i>Molecular Pharmacology</i> <b>47</b> :172-180 (1995)  |
| A59. | Schulz et al, "Radioimmunoassay for N-terminal probrain natriuretic peptide in human plasma" <i>Scand J Clin Lab Invest</i> <b>61</b> (1): 33-42 (February 2001)   |
| A60. | Seymour et al. "Potentiation of Natriuretic Peptides by Neutral Endopeptidase Inhibitors" <i>Clin Exp Pharmacol Physiol</i> <b>22</b> (1) 63-69 (January 1995) Abstract  |
| A61. | Sudoh et al. "Cloning and Sequence Analysis of cDNA Encoding a Precursor for Human Brain Natriuretic Peptide" <i>Biochemical and Biophysical Research Communications</i> <b>159</b> (3): 1427-1434 (March 31, 1989)                |
| A62. | Suga et al. "Receptor Selectivity of Natriuretic Peptide Family, Atrial Natriuretic Peptide, Brain Natriuretic Peptide, and C-Type Natriuretic Peptide" <i>Endocrinology</i> <b>130</b> (1): 229-239 (1992)                        |

EXAMINER  
\*EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



<b>FORM PTO-1449</b> U.S. Department of Commerce Patent and Trademark Office		Attorney Docket Number 9233-108	Serial No. 10/723,933
LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)		Applicants: James et al.	
		Filing Date November 26, 2003	Group
	A63.	Takeda et al "Brain Natriuretic Peptide in Hypertension" <i>Hypertens Res</i> 18(4): 259-266 ( December 1995) Abstract	
	A64.	Takei et al. "A New Natriuretic Peptide Isolated from Cardiac Atria of Trout, Oncorhynchus Mykiss" <i>FEBS Lett</i> 414(2): 377-380 (September 1997) Abstract	
	A65.	Takei, Y. "Does the Natriuretic Peptide System Exist Throughout the Animal and Plant Kingdom?" <i>Comp Biochem Physiol B. Biochem Mol Biol</i> 129(2-3): 559-573 (June 2001) Abstract	
	A66.	Uusimaa et al. "Plasma Vasoactive Peptides After Acute Myocardial Infarction in Relation to Left Ventricular Dysfunction" <i>Int J Cardiol</i> 69(1): 5-14 (April 1999) Abstract	
	A67.	Woods et al. "Atrial, B-type, and C-type Natriuretic Peptides Cause Mesenteric Vasoconstriction in Conscious Dogs" <i>Am. J. Physiol.</i> 276(Regulatory Integrative Comp. Physiol. 45): R1443-R1453 (1999)	
	A68.	Yamamoto et al. "Effect of Endogenous Natriuretic Peptide System on Ventricular and Coronary Function in Failing Heart" <i>Am. J. Physiol.</i> 273(Heart Circ. Physiol. 42): H2406-H2414 (1997)	

EXAMINER  
 \*EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.